Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Acadia Pharmaceutica
(NQ:
ACAD
)
16.18
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
16.18
Bid (Size)
13.95 (1)
Ask (Size)
18.50 (1)
Prev. Close
16.18
Today's Range
16.18 - 16.18
52wk Range
14.15 - 32.59
Shares Outstanding
162,625,379
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
November 21, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 15, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Performance
YTD
-47.57%
-47.57%
1 Month
+11.43%
+11.43%
3 Month
+3.19%
+3.19%
6 Month
+4.12%
+4.12%
1 Year
-26.42%
-26.42%
More News
Read More
Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?"
November 14, 2024
Via
MarketBeat
Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview
November 06, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Expert Outlook: ACADIA Pharmaceuticals Through The Eyes Of 5 Analysts
August 07, 2024
Via
Benzinga
A Closer Look at 13 Analyst Recommendations For ACADIA Pharmaceuticals
July 12, 2024
Via
Benzinga
Expert Ratings For ACADIA Pharmaceuticals
June 25, 2024
Via
Benzinga
Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
November 05, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
October 17, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome
October 16, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Critical Insights From ACADIA Pharmaceuticals Analyst Ratings: What You Need To Know
October 10, 2024
Via
Benzinga
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 08, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 26, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
What's Going On With ACADIA Pharmaceuticals Stock?
September 24, 2024
Via
Benzinga
Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals
September 23, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
August 28, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Jim Cramer Believes In Dell CEO, Doesn't Like B&G Foods
August 27, 2024
Via
Benzinga
Ryan Reynolds Announces More to Parkinson’s® Campaign
August 14, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 07, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'
August 07, 2024
Via
Investor's Business Daily
Topics
Earnings
Exposures
Financial
Airbnb Reports Weak Earnings, Joins Cryoport, Tripadvisor, Lyft And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
August 07, 2024
Via
Benzinga
Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview
August 06, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024
July 24, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med
July 18, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
June 27, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.